Form 4: Spruce Biosciences Chief Medical Officer Acquires 106,400 Restricted Stock Units
SEC Form 4 Filing
Ralph William Charlton III, Chief Medical Officer of Spruce Biosciences, reports the acquisition of 106,400 Restricted Stock Units (RSUs) on March 14, 2024.
Summary
- On March 14, 2024, Ralph William Charlton III, the Chief Medical Officer of Spruce Biosciences, acquired 106,400 Restricted Stock Units (RSUs).
- Each RSU represents a contingent right to receive one share of SPRB common stock.
- The RSUs vest in four equal installments of 25% on the first, second, third, and fourth anniversaries of achieving a specified clinical development objective, contingent upon the Reporting Person's Continuous Service.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing indicating an executive's compensation in the form of RSUs. It's neutral in sentiment as it simply reports a transaction.
Future Outlook
The vesting of the RSUs is contingent upon the achievement of a specified clinical development objective and the Reporting Person's Continuous Service, suggesting a link between executive compensation and company performance.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The acquisition of RSUs by the Chief Medical Officer aligns his interests with those of the shareholders, as the value of the RSUs is tied to the company's performance.
Key Dates
| Date | Description |
|---|---|
| 03/14/2024 | Date of transaction: Ralph William Charlton III acquired 106,400 Restricted Stock Units. |
| 03/18/2024 | Date of signature: Form 4 signed by Samir Gharib, Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.